nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—CYP3A5—Tacrolimus—atopic dermatitis	0.0355	0.142	CbGbCtD
Crizotinib—CYP3A4—Pimecrolimus—atopic dermatitis	0.0233	0.0934	CbGbCtD
Crizotinib—ABCB1—Tacrolimus—atopic dermatitis	0.0231	0.0927	CbGbCtD
Crizotinib—ABCB1—Loratadine—atopic dermatitis	0.0169	0.0678	CbGbCtD
Crizotinib—ABCB1—Methylprednisolone—atopic dermatitis	0.0155	0.062	CbGbCtD
Crizotinib—CYP3A5—Hydrocortisone—atopic dermatitis	0.0145	0.058	CbGbCtD
Crizotinib—CYP3A4—Tacrolimus—atopic dermatitis	0.0139	0.0555	CbGbCtD
Crizotinib—CYP3A4—Loratadine—atopic dermatitis	0.0101	0.0406	CbGbCtD
Crizotinib—ABCB1—Betamethasone—atopic dermatitis	0.0101	0.0403	CbGbCtD
Crizotinib—ABCB1—Prednisolone—atopic dermatitis	0.00993	0.0398	CbGbCtD
Crizotinib—ABCB1—Hydrocortisone—atopic dermatitis	0.00941	0.0377	CbGbCtD
Crizotinib—ABCB1—Prednisone—atopic dermatitis	0.00938	0.0376	CbGbCtD
Crizotinib—CYP3A4—Methylprednisolone—atopic dermatitis	0.00927	0.0372	CbGbCtD
Crizotinib—CYP3A5—Dexamethasone—atopic dermatitis	0.00899	0.036	CbGbCtD
Crizotinib—IGF1R—skin epidermis—atopic dermatitis	0.00739	0.0535	CbGeAlD
Crizotinib—CYP3A4—Triamcinolone—atopic dermatitis	0.00703	0.0282	CbGbCtD
Crizotinib—CYP3A4—Betamethasone—atopic dermatitis	0.00603	0.0242	CbGbCtD
Crizotinib—CYP3A4—Prednisolone—atopic dermatitis	0.00595	0.0238	CbGbCtD
Crizotinib—ABCB1—Dexamethasone—atopic dermatitis	0.00585	0.0235	CbGbCtD
Crizotinib—CYP3A4—Hydrocortisone—atopic dermatitis	0.00564	0.0226	CbGbCtD
Crizotinib—CYP3A4—Prednisone—atopic dermatitis	0.00562	0.0225	CbGbCtD
Crizotinib—PTK2—skin epidermis—atopic dermatitis	0.00549	0.0397	CbGeAlD
Crizotinib—MET—neck—atopic dermatitis	0.0045	0.0326	CbGeAlD
Crizotinib—IGF1R—neck—atopic dermatitis	0.00354	0.0256	CbGeAlD
Crizotinib—CYP3A4—Dexamethasone—atopic dermatitis	0.00351	0.0141	CbGbCtD
Crizotinib—ANKK1—head—atopic dermatitis	0.0035	0.0254	CbGeAlD
Crizotinib—BMP2K—neck—atopic dermatitis	0.00295	0.0214	CbGeAlD
Crizotinib—MET—skin of body—atopic dermatitis	0.00291	0.0211	CbGeAlD
Crizotinib—PTK2—neck—atopic dermatitis	0.00263	0.019	CbGeAlD
Crizotinib—TBK1—neck—atopic dermatitis	0.00263	0.019	CbGeAlD
Crizotinib—RPS6KB1—neck—atopic dermatitis	0.00253	0.0183	CbGeAlD
Crizotinib—NEK9—head—atopic dermatitis	0.00251	0.0182	CbGeAlD
Crizotinib—TYRO3—skin of body—atopic dermatitis	0.00238	0.0173	CbGeAlD
Crizotinib—IGF1R—skin of body—atopic dermatitis	0.00229	0.0166	CbGeAlD
Crizotinib—PRKD1—head—atopic dermatitis	0.00229	0.0166	CbGeAlD
Crizotinib—SIK2—head—atopic dermatitis	0.00226	0.0163	CbGeAlD
Crizotinib—LTK—head—atopic dermatitis	0.0021	0.0152	CbGeAlD
Crizotinib—MAPK7—head—atopic dermatitis	0.00203	0.0147	CbGeAlD
Crizotinib—TXK—head—atopic dermatitis	0.00203	0.0147	CbGeAlD
Crizotinib—EPHA8—head—atopic dermatitis	0.00201	0.0146	CbGeAlD
Crizotinib—STK35—skin of body—atopic dermatitis	0.00199	0.0144	CbGeAlD
Crizotinib—MET—head—atopic dermatitis	0.0019	0.0138	CbGeAlD
Crizotinib—CDK7—head—atopic dermatitis	0.00184	0.0133	CbGeAlD
Crizotinib—RIPK2—skin of body—atopic dermatitis	0.00183	0.0133	CbGeAlD
Crizotinib—EPHA3—head—atopic dermatitis	0.00176	0.0127	CbGeAlD
Crizotinib—ACVR1B—head—atopic dermatitis	0.00176	0.0127	CbGeAlD
Crizotinib—PTK2—skin of body—atopic dermatitis	0.0017	0.0123	CbGeAlD
Crizotinib—TYK2—skin of body—atopic dermatitis	0.00169	0.0122	CbGeAlD
Crizotinib—JAK3—head—atopic dermatitis	0.00168	0.0121	CbGeAlD
Crizotinib—EPHA6—head—atopic dermatitis	0.00168	0.0121	CbGeAlD
Crizotinib—DCLK1—head—atopic dermatitis	0.00167	0.0121	CbGeAlD
Crizotinib—STK4—head—atopic dermatitis	0.00165	0.0119	CbGeAlD
Crizotinib—AXL—skin of body—atopic dermatitis	0.00162	0.0117	CbGeAlD
Crizotinib—ALK—head—atopic dermatitis	0.00156	0.0113	CbGeAlD
Crizotinib—FER—head—atopic dermatitis	0.00156	0.0113	CbGeAlD
Crizotinib—TYRO3—head—atopic dermatitis	0.00156	0.0113	CbGeAlD
Crizotinib—EPHA5—head—atopic dermatitis	0.00156	0.0113	CbGeAlD
Crizotinib—LYN—head—atopic dermatitis	0.00155	0.0112	CbGeAlD
Crizotinib—JAK2—skin of body—atopic dermatitis	0.00154	0.0111	CbGeAlD
Crizotinib—BMPR1B—head—atopic dermatitis	0.00152	0.011	CbGeAlD
Crizotinib—MAP3K19—head—atopic dermatitis	0.00152	0.011	CbGeAlD
Crizotinib—IGF1R—head—atopic dermatitis	0.00149	0.0108	CbGeAlD
Crizotinib—TNK2—head—atopic dermatitis	0.00149	0.0108	CbGeAlD
Crizotinib—MAP3K3—skin of body—atopic dermatitis	0.00148	0.0107	CbGeAlD
Crizotinib—STK3—head—atopic dermatitis	0.00145	0.0105	CbGeAlD
Crizotinib—TIE1—head—atopic dermatitis	0.00145	0.0105	CbGeAlD
Crizotinib—AURKA—head—atopic dermatitis	0.00142	0.0103	CbGeAlD
Crizotinib—EPHB6—skin of body—atopic dermatitis	0.00142	0.0102	CbGeAlD
Crizotinib—TESK1—head—atopic dermatitis	0.00141	0.0102	CbGeAlD
Crizotinib—MERTK—head—atopic dermatitis	0.00137	0.0099	CbGeAlD
Crizotinib—LIMK2—head—atopic dermatitis	0.00134	0.00968	CbGeAlD
Crizotinib—MAP3K12—head—atopic dermatitis	0.00132	0.00958	CbGeAlD
Crizotinib—ACVR1—head—atopic dermatitis	0.00132	0.00958	CbGeAlD
Crizotinib—SRC—skin of body—atopic dermatitis	0.00132	0.00953	CbGeAlD
Crizotinib—STK35—head—atopic dermatitis	0.0013	0.00938	CbGeAlD
Crizotinib—BMP2K—head—atopic dermatitis	0.00125	0.00903	CbGeAlD
Crizotinib—PTK2B—head—atopic dermatitis	0.0012	0.00872	CbGeAlD
Crizotinib—RIPK2—head—atopic dermatitis	0.0012	0.00865	CbGeAlD
Crizotinib—CSF1R—skin of body—atopic dermatitis	0.00118	0.00855	CbGeAlD
Crizotinib—EPHA4—head—atopic dermatitis	0.00116	0.00836	CbGeAlD
Crizotinib—MAP3K2—head—atopic dermatitis	0.00113	0.0082	CbGeAlD
Crizotinib—TBK1—head—atopic dermatitis	0.00111	0.00803	CbGeAlD
Crizotinib—PTK2—head—atopic dermatitis	0.00111	0.00803	CbGeAlD
Crizotinib—TYK2—head—atopic dermatitis	0.0011	0.00798	CbGeAlD
Crizotinib—RPS6KB1—head—atopic dermatitis	0.00107	0.00773	CbGeAlD
Crizotinib—FGR—head—atopic dermatitis	0.00106	0.00768	CbGeAlD
Crizotinib—AXL—head—atopic dermatitis	0.00106	0.00765	CbGeAlD
Crizotinib—JAK2—head—atopic dermatitis	0.001	0.00726	CbGeAlD
Crizotinib—EPHA2—head—atopic dermatitis	0.000991	0.00717	CbGeAlD
Crizotinib—MAP3K3—head—atopic dermatitis	0.000966	0.007	CbGeAlD
Crizotinib—TEK—head—atopic dermatitis	0.000966	0.007	CbGeAlD
Crizotinib—MAP4K5—head—atopic dermatitis	0.000966	0.007	CbGeAlD
Crizotinib—CASK—Temsirolimus—Tacrolimus—atopic dermatitis	0.000963	0.101	CbGdCrCtD
Crizotinib—CASK—Temsirolimus—Pimecrolimus—atopic dermatitis	0.000963	0.101	CbGdCrCtD
Crizotinib—ABL1—skin of body—atopic dermatitis	0.000934	0.00676	CbGeAlD
Crizotinib—EPHB6—head—atopic dermatitis	0.000924	0.00669	CbGeAlD
Crizotinib—YES1—head—atopic dermatitis	0.000892	0.00646	CbGeAlD
Crizotinib—STK10—head—atopic dermatitis	0.000884	0.0064	CbGeAlD
Crizotinib—TAOK3—head—atopic dermatitis	0.000881	0.00638	CbGeAlD
Crizotinib—SRC—head—atopic dermatitis	0.000859	0.00622	CbGeAlD
Crizotinib—CSF1R—head—atopic dermatitis	0.000771	0.00558	CbGeAlD
Crizotinib—ABL1—head—atopic dermatitis	0.000609	0.00441	CbGeAlD
Crizotinib—Vomiting—Pimecrolimus—atopic dermatitis	0.000486	0.00195	CcSEcCtD
Crizotinib—Rash—Pimecrolimus—atopic dermatitis	0.000482	0.00193	CcSEcCtD
Crizotinib—Dermatitis—Pimecrolimus—atopic dermatitis	0.000481	0.00193	CcSEcCtD
Crizotinib—Body temperature increased—Loratadine—atopic dermatitis	0.000481	0.00193	CcSEcCtD
Crizotinib—Hypokalaemia—Hydrocortisone—atopic dermatitis	0.00048	0.00193	CcSEcCtD
Crizotinib—Vision blurred—Tacrolimus—atopic dermatitis	0.00048	0.00192	CcSEcCtD
Crizotinib—Muscular weakness—Prednisolone—atopic dermatitis	0.000476	0.00191	CcSEcCtD
Crizotinib—Visual disturbance—Betamethasone—atopic dermatitis	0.000476	0.00191	CcSEcCtD
Crizotinib—Visual disturbance—Dexamethasone—atopic dermatitis	0.000476	0.00191	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Fluocinolone Acetonide—atopic dermatitis	0.000472	0.00189	CcSEcCtD
Crizotinib—Anaemia—Tacrolimus—atopic dermatitis	0.000471	0.00189	CcSEcCtD
Crizotinib—Nausea—Diphenhydramine—atopic dermatitis	0.000469	0.00188	CcSEcCtD
Crizotinib—Nausea—Dimenhydrinate—atopic dermatitis	0.000469	0.00188	CcSEcCtD
Crizotinib—Sepsis—Prednisone—atopic dermatitis	0.000469	0.00188	CcSEcCtD
Crizotinib—Paraesthesia—Mometasone—atopic dermatitis	0.000469	0.00188	CcSEcCtD
Crizotinib—Dyspnoea—Mometasone—atopic dermatitis	0.000466	0.00187	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Hydrocortisone—atopic dermatitis	0.000465	0.00187	CcSEcCtD
Crizotinib—Muscular weakness—Hydrocortisone—atopic dermatitis	0.000465	0.00187	CcSEcCtD
Crizotinib—Dyspepsia—Mometasone—atopic dermatitis	0.00046	0.00184	CcSEcCtD
Crizotinib—Syncope—Tacrolimus—atopic dermatitis	0.000457	0.00183	CcSEcCtD
Crizotinib—Leukopenia—Tacrolimus—atopic dermatitis	0.000456	0.00183	CcSEcCtD
Crizotinib—Decreased appetite—Mometasone—atopic dermatitis	0.000454	0.00182	CcSEcCtD
Crizotinib—Nausea—Pimecrolimus—atopic dermatitis	0.000454	0.00182	CcSEcCtD
Crizotinib—Fatigue—Mometasone—atopic dermatitis	0.00045	0.00181	CcSEcCtD
Crizotinib—Loss of consciousness—Tacrolimus—atopic dermatitis	0.000448	0.00179	CcSEcCtD
Crizotinib—Muscular weakness—Triamcinolone—atopic dermatitis	0.000438	0.00176	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Methylprednisolone—atopic dermatitis	0.000437	0.00175	CcSEcCtD
Crizotinib—Muscular weakness—Methylprednisolone—atopic dermatitis	0.000437	0.00175	CcSEcCtD
Crizotinib—Asthenia—Loratadine—atopic dermatitis	0.000437	0.00175	CcSEcCtD
Crizotinib—Body temperature increased—Fluocinolone Acetonide—atopic dermatitis	0.000432	0.00173	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Tacrolimus—atopic dermatitis	0.000431	0.00173	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Hydrocortisone—atopic dermatitis	0.000424	0.0017	CcSEcCtD
Crizotinib—Diarrhoea—Loratadine—atopic dermatitis	0.000416	0.00167	CcSEcCtD
Crizotinib—Oedema—Tacrolimus—atopic dermatitis	0.000416	0.00167	CcSEcCtD
Crizotinib—Infection—Tacrolimus—atopic dermatitis	0.000413	0.00166	CcSEcCtD
Crizotinib—Body temperature increased—Mometasone—atopic dermatitis	0.000413	0.00166	CcSEcCtD
Crizotinib—Weight decreased—Hydrocortisone—atopic dermatitis	0.000413	0.00165	CcSEcCtD
Crizotinib—Hypokalaemia—Betamethasone—atopic dermatitis	0.00041	0.00164	CcSEcCtD
Crizotinib—Hypokalaemia—Dexamethasone—atopic dermatitis	0.00041	0.00164	CcSEcCtD
Crizotinib—Shock—Tacrolimus—atopic dermatitis	0.000409	0.00164	CcSEcCtD
Crizotinib—Neuropathy peripheral—Prednisolone—atopic dermatitis	0.000408	0.00164	CcSEcCtD
Crizotinib—Nervous system disorder—Tacrolimus—atopic dermatitis	0.000408	0.00163	CcSEcCtD
Crizotinib—Infestation NOS—Hydrocortisone—atopic dermatitis	0.000407	0.00163	CcSEcCtD
Crizotinib—Infestation—Hydrocortisone—atopic dermatitis	0.000407	0.00163	CcSEcCtD
Crizotinib—Skin disorder—Tacrolimus—atopic dermatitis	0.000404	0.00162	CcSEcCtD
Crizotinib—Dizziness—Loratadine—atopic dermatitis	0.000402	0.00161	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Triamcinolone—atopic dermatitis	0.000399	0.0016	CcSEcCtD
Crizotinib—Neuropathy peripheral—Hydrocortisone—atopic dermatitis	0.000399	0.0016	CcSEcCtD
Crizotinib—Muscular weakness—Betamethasone—atopic dermatitis	0.000398	0.00159	CcSEcCtD
Crizotinib—Muscular weakness—Dexamethasone—atopic dermatitis	0.000398	0.00159	CcSEcCtD
Crizotinib—Vomiting—Loratadine—atopic dermatitis	0.000387	0.00155	CcSEcCtD
Crizotinib—Rash—Loratadine—atopic dermatitis	0.000384	0.00154	CcSEcCtD
Crizotinib—Dermatitis—Loratadine—atopic dermatitis	0.000383	0.00154	CcSEcCtD
Crizotinib—Infestation NOS—Methylprednisolone—atopic dermatitis	0.000382	0.00153	CcSEcCtD
Crizotinib—Infestation—Methylprednisolone—atopic dermatitis	0.000382	0.00153	CcSEcCtD
Crizotinib—Bradycardia—Prednisolone—atopic dermatitis	0.00038	0.00153	CcSEcCtD
Crizotinib—Face oedema—Prednisone—atopic dermatitis	0.000379	0.00152	CcSEcCtD
Crizotinib—Neuropathy peripheral—Triamcinolone—atopic dermatitis	0.000375	0.0015	CcSEcCtD
Crizotinib—Asthenia—Mometasone—atopic dermatitis	0.000375	0.0015	CcSEcCtD
Crizotinib—Neuropathy peripheral—Methylprednisolone—atopic dermatitis	0.000374	0.0015	CcSEcCtD
Crizotinib—Diarrhoea—Fluocinolone Acetonide—atopic dermatitis	0.000374	0.0015	CcSEcCtD
Crizotinib—Paraesthesia—Tacrolimus—atopic dermatitis	0.000373	0.0015	CcSEcCtD
Crizotinib—AURKA—Temsirolimus—Tacrolimus—atopic dermatitis	0.000372	0.0392	CbGdCrCtD
Crizotinib—AURKA—Sirolimus—Pimecrolimus—atopic dermatitis	0.000372	0.0392	CbGdCrCtD
Crizotinib—AURKA—Temsirolimus—Pimecrolimus—atopic dermatitis	0.000372	0.0392	CbGdCrCtD
Crizotinib—AURKA—Sirolimus—Tacrolimus—atopic dermatitis	0.000372	0.0392	CbGdCrCtD
Crizotinib—Bradycardia—Hydrocortisone—atopic dermatitis	0.000372	0.00149	CcSEcCtD
Crizotinib—Dyspnoea—Tacrolimus—atopic dermatitis	0.000371	0.00149	CcSEcCtD
Crizotinib—Dyspepsia—Tacrolimus—atopic dermatitis	0.000366	0.00147	CcSEcCtD
Crizotinib—Dizziness—Fluocinolone Acetonide—atopic dermatitis	0.000362	0.00145	CcSEcCtD
Crizotinib—Nausea—Loratadine—atopic dermatitis	0.000361	0.00145	CcSEcCtD
Crizotinib—Decreased appetite—Tacrolimus—atopic dermatitis	0.000361	0.00145	CcSEcCtD
Crizotinib—Visual impairment—Prednisolone—atopic dermatitis	0.00036	0.00144	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Tacrolimus—atopic dermatitis	0.000359	0.00144	CcSEcCtD
Crizotinib—Fatigue—Tacrolimus—atopic dermatitis	0.000358	0.00144	CcSEcCtD
Crizotinib—Diarrhoea—Mometasone—atopic dermatitis	0.000357	0.00143	CcSEcCtD
Crizotinib—Hypokalaemia—Prednisone—atopic dermatitis	0.000357	0.00143	CcSEcCtD
Crizotinib—Constipation—Tacrolimus—atopic dermatitis	0.000355	0.00143	CcSEcCtD
Crizotinib—Weight decreased—Dexamethasone—atopic dermatitis	0.000352	0.00141	CcSEcCtD
Crizotinib—Weight decreased—Betamethasone—atopic dermatitis	0.000352	0.00141	CcSEcCtD
Crizotinib—Bradycardia—Triamcinolone—atopic dermatitis	0.00035	0.0014	CcSEcCtD
Crizotinib—Bradycardia—Methylprednisolone—atopic dermatitis	0.000349	0.0014	CcSEcCtD
Crizotinib—Vomiting—Fluocinolone Acetonide—atopic dermatitis	0.000348	0.00139	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Prednisone—atopic dermatitis	0.000346	0.00139	CcSEcCtD
Crizotinib—Muscular weakness—Prednisone—atopic dermatitis	0.000346	0.00139	CcSEcCtD
Crizotinib—Rash—Fluocinolone Acetonide—atopic dermatitis	0.000345	0.00138	CcSEcCtD
Crizotinib—Dermatitis—Fluocinolone Acetonide—atopic dermatitis	0.000345	0.00138	CcSEcCtD
Crizotinib—Eye disorder—Hydrocortisone—atopic dermatitis	0.000341	0.00137	CcSEcCtD
Crizotinib—Neuropathy peripheral—Betamethasone—atopic dermatitis	0.00034	0.00137	CcSEcCtD
Crizotinib—Neuropathy peripheral—Dexamethasone—atopic dermatitis	0.00034	0.00137	CcSEcCtD
Crizotinib—Arrhythmia—Prednisolone—atopic dermatitis	0.000334	0.00134	CcSEcCtD
Crizotinib—Vomiting—Mometasone—atopic dermatitis	0.000332	0.00133	CcSEcCtD
Crizotinib—Visual impairment—Methylprednisolone—atopic dermatitis	0.00033	0.00132	CcSEcCtD
Crizotinib—Rash—Mometasone—atopic dermatitis	0.000329	0.00132	CcSEcCtD
Crizotinib—Dermatitis—Mometasone—atopic dermatitis	0.000329	0.00132	CcSEcCtD
Crizotinib—Body temperature increased—Tacrolimus—atopic dermatitis	0.000329	0.00132	CcSEcCtD
Crizotinib—ACVR1—Dexamethasone—Desonide—atopic dermatitis	0.000327	0.0345	CbGdCrCtD
Crizotinib—ACVR1—Betamethasone—Desonide—atopic dermatitis	0.000327	0.0345	CbGdCrCtD
Crizotinib—Arrhythmia—Hydrocortisone—atopic dermatitis	0.000326	0.00131	CcSEcCtD
Crizotinib—Nausea—Fluocinolone Acetonide—atopic dermatitis	0.000325	0.0013	CcSEcCtD
Crizotinib—Eye disorder—Methylprednisolone—atopic dermatitis	0.00032	0.00128	CcSEcCtD
Crizotinib—Cardiac disorder—Methylprednisolone—atopic dermatitis	0.000318	0.00128	CcSEcCtD
Crizotinib—Malnutrition—Hydrocortisone—atopic dermatitis	0.000318	0.00127	CcSEcCtD
Crizotinib—Bradycardia—Dexamethasone—atopic dermatitis	0.000317	0.00127	CcSEcCtD
Crizotinib—Bradycardia—Betamethasone—atopic dermatitis	0.000317	0.00127	CcSEcCtD
Crizotinib—Neutropenia—Prednisone—atopic dermatitis	0.000317	0.00127	CcSEcCtD
Crizotinib—Nausea—Mometasone—atopic dermatitis	0.00031	0.00124	CcSEcCtD
Crizotinib—Mediastinal disorder—Methylprednisolone—atopic dermatitis	0.000309	0.00124	CcSEcCtD
Crizotinib—PTK2B—Carbinoxamine—Diphenhydramine—atopic dermatitis	0.000308	0.0325	CbGdCrCtD
Crizotinib—Arrhythmia—Triamcinolone—atopic dermatitis	0.000307	0.00123	CcSEcCtD
Crizotinib—Weight decreased—Prednisone—atopic dermatitis	0.000307	0.00123	CcSEcCtD
Crizotinib—Vision blurred—Prednisolone—atopic dermatitis	0.000307	0.00123	CcSEcCtD
Crizotinib—Arrhythmia—Methylprednisolone—atopic dermatitis	0.000306	0.00123	CcSEcCtD
Crizotinib—Visual impairment—Dexamethasone—atopic dermatitis	0.000301	0.0012	CcSEcCtD
Crizotinib—Visual impairment—Betamethasone—atopic dermatitis	0.000301	0.0012	CcSEcCtD
Crizotinib—Malnutrition—Methylprednisolone—atopic dermatitis	0.000299	0.0012	CcSEcCtD
Crizotinib—Asthenia—Tacrolimus—atopic dermatitis	0.000298	0.0012	CcSEcCtD
Crizotinib—Neuropathy peripheral—Prednisone—atopic dermatitis	0.000297	0.00119	CcSEcCtD
Crizotinib—Dysgeusia—Triamcinolone—atopic dermatitis	0.000293	0.00117	CcSEcCtD
Crizotinib—Syncope—Prednisolone—atopic dermatitis	0.000292	0.00117	CcSEcCtD
Crizotinib—Eye disorder—Dexamethasone—atopic dermatitis	0.000291	0.00117	CcSEcCtD
Crizotinib—Eye disorder—Betamethasone—atopic dermatitis	0.000291	0.00117	CcSEcCtD
Crizotinib—Loss of consciousness—Prednisolone—atopic dermatitis	0.000286	0.00115	CcSEcCtD
Crizotinib—Syncope—Hydrocortisone—atopic dermatitis	0.000285	0.00114	CcSEcCtD
Crizotinib—Diarrhoea—Tacrolimus—atopic dermatitis	0.000284	0.00114	CcSEcCtD
Crizotinib—Loss of consciousness—Hydrocortisone—atopic dermatitis	0.000279	0.00112	CcSEcCtD
Crizotinib—Arrhythmia—Betamethasone—atopic dermatitis	0.000279	0.00112	CcSEcCtD
Crizotinib—Arrhythmia—Dexamethasone—atopic dermatitis	0.000279	0.00112	CcSEcCtD
Crizotinib—Bradycardia—Prednisone—atopic dermatitis	0.000276	0.00111	CcSEcCtD
Crizotinib—Dizziness—Tacrolimus—atopic dermatitis	0.000275	0.0011	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—atopic dermatitis	0.000269	0.00108	CcSEcCtD
Crizotinib—Syncope—Triamcinolone—atopic dermatitis	0.000268	0.00108	CcSEcCtD
Crizotinib—Syncope—Methylprednisolone—atopic dermatitis	0.000268	0.00107	CcSEcCtD
Crizotinib—Oedema—Prednisolone—atopic dermatitis	0.000266	0.00106	CcSEcCtD
Crizotinib—Vomiting—Tacrolimus—atopic dermatitis	0.000264	0.00106	CcSEcCtD
Crizotinib—Loss of consciousness—Triamcinolone—atopic dermatitis	0.000263	0.00105	CcSEcCtD
Crizotinib—Loss of consciousness—Methylprednisolone—atopic dermatitis	0.000262	0.00105	CcSEcCtD
Crizotinib—ACVR1—Dexamethasone—Fluocinonide—atopic dermatitis	0.000262	0.0276	CbGdCrCtD
Crizotinib—ACVR1—Betamethasone—Fluocinonide—atopic dermatitis	0.000262	0.0276	CbGdCrCtD
Crizotinib—Rash—Tacrolimus—atopic dermatitis	0.000262	0.00105	CcSEcCtD
Crizotinib—Dermatitis—Tacrolimus—atopic dermatitis	0.000262	0.00105	CcSEcCtD
Crizotinib—Shock—Prednisolone—atopic dermatitis	0.000261	0.00105	CcSEcCtD
Crizotinib—Oedema—Hydrocortisone—atopic dermatitis	0.000259	0.00104	CcSEcCtD
Crizotinib—Infection—Hydrocortisone—atopic dermatitis	0.000258	0.00103	CcSEcCtD
Crizotinib—Shock—Hydrocortisone—atopic dermatitis	0.000255	0.00102	CcSEcCtD
Crizotinib—ACVR1—Dexamethasone—Fluocinolone Acetonide—atopic dermatitis	0.000255	0.0269	CbGdCrCtD
Crizotinib—ACVR1—Betamethasone—Fluocinolone Acetonide—atopic dermatitis	0.000255	0.0269	CbGdCrCtD
Crizotinib—Nervous system disorder—Hydrocortisone—atopic dermatitis	0.000254	0.00102	CcSEcCtD
Crizotinib—Eye disorder—Prednisone—atopic dermatitis	0.000254	0.00102	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—atopic dermatitis	0.000252	0.00101	CcSEcCtD
Crizotinib—Skin disorder—Hydrocortisone—atopic dermatitis	0.000252	0.00101	CcSEcCtD
Crizotinib—Nausea—Tacrolimus—atopic dermatitis	0.000247	0.00099	CcSEcCtD
Crizotinib—Oedema—Triamcinolone—atopic dermatitis	0.000244	0.000979	CcSEcCtD
Crizotinib—Syncope—Betamethasone—atopic dermatitis	0.000243	0.000976	CcSEcCtD
Crizotinib—Syncope—Dexamethasone—atopic dermatitis	0.000243	0.000976	CcSEcCtD
Crizotinib—Arrhythmia—Prednisone—atopic dermatitis	0.000243	0.000973	CcSEcCtD
Crizotinib—Infection—Triamcinolone—atopic dermatitis	0.000243	0.000973	CcSEcCtD
Crizotinib—Infection—Methylprednisolone—atopic dermatitis	0.000242	0.00097	CcSEcCtD
Crizotinib—Shock—Triamcinolone—atopic dermatitis	0.00024	0.000963	CcSEcCtD
Crizotinib—Shock—Methylprednisolone—atopic dermatitis	0.00024	0.000961	CcSEcCtD
Crizotinib—Nervous system disorder—Methylprednisolone—atopic dermatitis	0.000239	0.000958	CcSEcCtD
Crizotinib—Loss of consciousness—Dexamethasone—atopic dermatitis	0.000239	0.000957	CcSEcCtD
Crizotinib—Loss of consciousness—Betamethasone—atopic dermatitis	0.000239	0.000957	CcSEcCtD
Crizotinib—Paraesthesia—Prednisolone—atopic dermatitis	0.000238	0.000956	CcSEcCtD
Crizotinib—Skin disorder—Methylprednisolone—atopic dermatitis	0.000237	0.000949	CcSEcCtD
Crizotinib—Malnutrition—Prednisone—atopic dermatitis	0.000236	0.000948	CcSEcCtD
Crizotinib—Paraesthesia—Hydrocortisone—atopic dermatitis	0.000233	0.000934	CcSEcCtD
Crizotinib—Dyspepsia—Hydrocortisone—atopic dermatitis	0.000228	0.000915	CcSEcCtD
Crizotinib—Decreased appetite—Hydrocortisone—atopic dermatitis	0.000225	0.000904	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Hydrocortisone—atopic dermatitis	0.000224	0.000898	CcSEcCtD
Crizotinib—Fatigue—Hydrocortisone—atopic dermatitis	0.000224	0.000896	CcSEcCtD
Crizotinib—Vision blurred—Prednisone—atopic dermatitis	0.000223	0.000893	CcSEcCtD
Crizotinib—Oedema—Betamethasone—atopic dermatitis	0.000222	0.000888	CcSEcCtD
Crizotinib—Oedema—Dexamethasone—atopic dermatitis	0.000222	0.000888	CcSEcCtD
Crizotinib—Infection—Betamethasone—atopic dermatitis	0.00022	0.000882	CcSEcCtD
Crizotinib—Infection—Dexamethasone—atopic dermatitis	0.00022	0.000882	CcSEcCtD
Crizotinib—Paraesthesia—Triamcinolone—atopic dermatitis	0.000219	0.000879	CcSEcCtD
Crizotinib—Paraesthesia—Methylprednisolone—atopic dermatitis	0.000219	0.000877	CcSEcCtD
Crizotinib—Anaemia—Prednisone—atopic dermatitis	0.000218	0.000876	CcSEcCtD
Crizotinib—Shock—Betamethasone—atopic dermatitis	0.000218	0.000874	CcSEcCtD
Crizotinib—Shock—Dexamethasone—atopic dermatitis	0.000218	0.000874	CcSEcCtD
Crizotinib—Dyspnoea—Triamcinolone—atopic dermatitis	0.000218	0.000873	CcSEcCtD
Crizotinib—Nervous system disorder—Dexamethasone—atopic dermatitis	0.000217	0.000871	CcSEcCtD
Crizotinib—Nervous system disorder—Betamethasone—atopic dermatitis	0.000217	0.000871	CcSEcCtD
Crizotinib—Dyspepsia—Triamcinolone—atopic dermatitis	0.000215	0.000862	CcSEcCtD
Crizotinib—Dyspepsia—Methylprednisolone—atopic dermatitis	0.000214	0.00086	CcSEcCtD
Crizotinib—Syncope—Prednisone—atopic dermatitis	0.000212	0.00085	CcSEcCtD
Crizotinib—TESK1—Dexamethasone—Desonide—atopic dermatitis	0.000211	0.0222	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Desonide—atopic dermatitis	0.000211	0.0222	CbGdCrCtD
Crizotinib—Fatigue—Triamcinolone—atopic dermatitis	0.000211	0.000844	CcSEcCtD
Crizotinib—Fatigue—Methylprednisolone—atopic dermatitis	0.00021	0.000842	CcSEcCtD
Crizotinib—Loss of consciousness—Prednisone—atopic dermatitis	0.000208	0.000833	CcSEcCtD
Crizotinib—Body temperature increased—Hydrocortisone—atopic dermatitis	0.000205	0.000822	CcSEcCtD
Crizotinib—ACVR1—Betamethasone—Mometasone—atopic dermatitis	0.000203	0.0214	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Mometasone—atopic dermatitis	0.000203	0.0214	CbGdCrCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—atopic dermatitis	0.0002	0.000801	CcSEcCtD
Crizotinib—Paraesthesia—Betamethasone—atopic dermatitis	0.000199	0.000798	CcSEcCtD
Crizotinib—Paraesthesia—Dexamethasone—atopic dermatitis	0.000199	0.000798	CcSEcCtD
Crizotinib—Dyspepsia—Dexamethasone—atopic dermatitis	0.000195	0.000782	CcSEcCtD
Crizotinib—Dyspepsia—Betamethasone—atopic dermatitis	0.000195	0.000782	CcSEcCtD
Crizotinib—Body temperature increased—Triamcinolone—atopic dermatitis	0.000193	0.000774	CcSEcCtD
Crizotinib—Oedema—Prednisone—atopic dermatitis	0.000193	0.000774	CcSEcCtD
Crizotinib—Decreased appetite—Dexamethasone—atopic dermatitis	0.000193	0.000772	CcSEcCtD
Crizotinib—Decreased appetite—Betamethasone—atopic dermatitis	0.000193	0.000772	CcSEcCtD
Crizotinib—Infection—Prednisone—atopic dermatitis	0.000192	0.000768	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Dexamethasone—atopic dermatitis	0.000191	0.000767	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Betamethasone—atopic dermatitis	0.000191	0.000767	CcSEcCtD
Crizotinib—Fatigue—Betamethasone—atopic dermatitis	0.000191	0.000766	CcSEcCtD
Crizotinib—Fatigue—Dexamethasone—atopic dermatitis	0.000191	0.000766	CcSEcCtD
Crizotinib—Shock—Prednisone—atopic dermatitis	0.00019	0.000761	CcSEcCtD
Crizotinib—ABCB1—head—atopic dermatitis	0.000189	0.00137	CbGeAlD
Crizotinib—Nervous system disorder—Prednisone—atopic dermatitis	0.000189	0.000759	CcSEcCtD
Crizotinib—Skin disorder—Prednisone—atopic dermatitis	0.000187	0.000751	CcSEcCtD
Crizotinib—Asthenia—Hydrocortisone—atopic dermatitis	0.000186	0.000746	CcSEcCtD
Crizotinib—Diarrhoea—Hydrocortisone—atopic dermatitis	0.000177	0.000711	CcSEcCtD
Crizotinib—Dizziness—Prednisolone—atopic dermatitis	0.000176	0.000704	CcSEcCtD
Crizotinib—Asthenia—Triamcinolone—atopic dermatitis	0.000175	0.000702	CcSEcCtD
Crizotinib—Body temperature increased—Betamethasone—atopic dermatitis	0.000175	0.000702	CcSEcCtD
Crizotinib—Body temperature increased—Dexamethasone—atopic dermatitis	0.000175	0.000702	CcSEcCtD
Crizotinib—Asthenia—Methylprednisolone—atopic dermatitis	0.000175	0.000701	CcSEcCtD
Crizotinib—Paraesthesia—Prednisone—atopic dermatitis	0.000173	0.000695	CcSEcCtD
Crizotinib—Dizziness—Hydrocortisone—atopic dermatitis	0.000171	0.000687	CcSEcCtD
Crizotinib—Dyspepsia—Prednisone—atopic dermatitis	0.00017	0.000681	CcSEcCtD
Crizotinib—TESK1—Dexamethasone—Fluocinonide—atopic dermatitis	0.000169	0.0178	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Fluocinonide—atopic dermatitis	0.000169	0.0178	CbGdCrCtD
Crizotinib—Decreased appetite—Prednisone—atopic dermatitis	0.000168	0.000672	CcSEcCtD
Crizotinib—Rash—Prednisolone—atopic dermatitis	0.000167	0.000671	CcSEcCtD
Crizotinib—Dermatitis—Prednisolone—atopic dermatitis	0.000167	0.000671	CcSEcCtD
Crizotinib—Diarrhoea—Methylprednisolone—atopic dermatitis	0.000167	0.000668	CcSEcCtD
Crizotinib—Fatigue—Prednisone—atopic dermatitis	0.000166	0.000667	CcSEcCtD
Crizotinib—Constipation—Prednisone—atopic dermatitis	0.000165	0.000661	CcSEcCtD
Crizotinib—Vomiting—Hydrocortisone—atopic dermatitis	0.000165	0.000661	CcSEcCtD
Crizotinib—TESK1—Dexamethasone—Fluocinolone Acetonide—atopic dermatitis	0.000164	0.0173	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Fluocinolone Acetonide—atopic dermatitis	0.000164	0.0173	CbGdCrCtD
Crizotinib—Rash—Hydrocortisone—atopic dermatitis	0.000163	0.000655	CcSEcCtD
Crizotinib—Dermatitis—Hydrocortisone—atopic dermatitis	0.000163	0.000655	CcSEcCtD
Crizotinib—Dizziness—Triamcinolone—atopic dermatitis	0.000161	0.000647	CcSEcCtD
Crizotinib—Dizziness—Methylprednisolone—atopic dermatitis	0.000161	0.000646	CcSEcCtD
Crizotinib—Asthenia—Dexamethasone—atopic dermatitis	0.000159	0.000637	CcSEcCtD
Crizotinib—Asthenia—Betamethasone—atopic dermatitis	0.000159	0.000637	CcSEcCtD
Crizotinib—Nausea—Prednisolone—atopic dermatitis	0.000158	0.000632	CcSEcCtD
Crizotinib—Vomiting—Triamcinolone—atopic dermatitis	0.000155	0.000622	CcSEcCtD
Crizotinib—Vomiting—Methylprednisolone—atopic dermatitis	0.000155	0.000621	CcSEcCtD
Crizotinib—Nausea—Hydrocortisone—atopic dermatitis	0.000154	0.000618	CcSEcCtD
Crizotinib—Rash—Triamcinolone—atopic dermatitis	0.000154	0.000617	CcSEcCtD
Crizotinib—Dermatitis—Triamcinolone—atopic dermatitis	0.000154	0.000617	CcSEcCtD
Crizotinib—Rash—Methylprednisolone—atopic dermatitis	0.000154	0.000616	CcSEcCtD
Crizotinib—Dermatitis—Methylprednisolone—atopic dermatitis	0.000153	0.000615	CcSEcCtD
Crizotinib—Body temperature increased—Prednisone—atopic dermatitis	0.000153	0.000611	CcSEcCtD
Crizotinib—Diarrhoea—Betamethasone—atopic dermatitis	0.000152	0.000608	CcSEcCtD
Crizotinib—Diarrhoea—Dexamethasone—atopic dermatitis	0.000152	0.000608	CcSEcCtD
Crizotinib—Dizziness—Betamethasone—atopic dermatitis	0.000147	0.000587	CcSEcCtD
Crizotinib—Dizziness—Dexamethasone—atopic dermatitis	0.000147	0.000587	CcSEcCtD
Crizotinib—Nausea—Triamcinolone—atopic dermatitis	0.000145	0.000581	CcSEcCtD
Crizotinib—Nausea—Methylprednisolone—atopic dermatitis	0.000145	0.00058	CcSEcCtD
Crizotinib—Vomiting—Dexamethasone—atopic dermatitis	0.000141	0.000565	CcSEcCtD
Crizotinib—Vomiting—Betamethasone—atopic dermatitis	0.000141	0.000565	CcSEcCtD
Crizotinib—Rash—Betamethasone—atopic dermatitis	0.00014	0.00056	CcSEcCtD
Crizotinib—Rash—Dexamethasone—atopic dermatitis	0.00014	0.00056	CcSEcCtD
Crizotinib—Dermatitis—Betamethasone—atopic dermatitis	0.00014	0.00056	CcSEcCtD
Crizotinib—Dermatitis—Dexamethasone—atopic dermatitis	0.00014	0.00056	CcSEcCtD
Crizotinib—Asthenia—Prednisone—atopic dermatitis	0.000138	0.000555	CcSEcCtD
Crizotinib—Diarrhoea—Prednisone—atopic dermatitis	0.000132	0.000529	CcSEcCtD
Crizotinib—Nausea—Dexamethasone—atopic dermatitis	0.000132	0.000528	CcSEcCtD
Crizotinib—Nausea—Betamethasone—atopic dermatitis	0.000132	0.000528	CcSEcCtD
Crizotinib—TESK1—Betamethasone—Mometasone—atopic dermatitis	0.000131	0.0138	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Mometasone—atopic dermatitis	0.000131	0.0138	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Hydrocortisone—atopic dermatitis	0.000129	0.0136	CbGdCrCtD
Crizotinib—ACVR1—Betamethasone—Hydrocortisone—atopic dermatitis	0.000129	0.0136	CbGdCrCtD
Crizotinib—Dizziness—Prednisone—atopic dermatitis	0.000128	0.000512	CcSEcCtD
Crizotinib—Vomiting—Prednisone—atopic dermatitis	0.000123	0.000492	CcSEcCtD
Crizotinib—Rash—Prednisone—atopic dermatitis	0.000122	0.000488	CcSEcCtD
Crizotinib—Dermatitis—Prednisone—atopic dermatitis	0.000122	0.000487	CcSEcCtD
Crizotinib—ACVR1—Betamethasone—Methylprednisolone—atopic dermatitis	0.000121	0.0128	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Methylprednisolone—atopic dermatitis	0.000121	0.0128	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Betamethasone—atopic dermatitis	0.00012	0.0126	CbGdCrCtD
Crizotinib—ACVR1—Betamethasone—Dexamethasone—atopic dermatitis	0.00012	0.0126	CbGdCrCtD
Crizotinib—ACVR1—Betamethasone—Triamcinolone—atopic dermatitis	0.000117	0.0123	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Triamcinolone—atopic dermatitis	0.000117	0.0123	CbGdCrCtD
Crizotinib—Nausea—Prednisone—atopic dermatitis	0.000115	0.000459	CcSEcCtD
Crizotinib—ACVR1—Betamethasone—Prednisone—atopic dermatitis	0.000111	0.0117	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Prednisone—atopic dermatitis	0.000111	0.0117	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Prednisolone—atopic dermatitis	0.000108	0.0114	CbGdCrCtD
Crizotinib—ACVR1—Betamethasone—Prednisolone—atopic dermatitis	0.000108	0.0114	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Hydrocortisone—atopic dermatitis	8.29e-05	0.00874	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Hydrocortisone—atopic dermatitis	8.29e-05	0.00874	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Methylprednisolone—atopic dermatitis	7.83e-05	0.00825	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Methylprednisolone—atopic dermatitis	7.83e-05	0.00825	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Betamethasone—atopic dermatitis	7.7e-05	0.00812	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Dexamethasone—atopic dermatitis	7.7e-05	0.00812	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Triamcinolone—atopic dermatitis	7.53e-05	0.00793	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Triamcinolone—atopic dermatitis	7.53e-05	0.00793	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Prednisone—atopic dermatitis	7.14e-05	0.00753	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Prednisone—atopic dermatitis	7.14e-05	0.00753	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Prednisolone—atopic dermatitis	6.97e-05	0.00735	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Prednisolone—atopic dermatitis	6.97e-05	0.00735	CbGdCrCtD
Crizotinib—JAK2—Signaling Pathways—IL5—atopic dermatitis	1.05e-05	2.98e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—MAPK8—atopic dermatitis	1.05e-05	2.97e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CCL5—atopic dermatitis	1.05e-05	2.97e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL18—atopic dermatitis	1.05e-05	2.96e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—MAPK8—atopic dermatitis	1.04e-05	2.96e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—MAPK8—atopic dermatitis	1.04e-05	2.95e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—MAPK8—atopic dermatitis	1.04e-05	2.94e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—NGF—atopic dermatitis	1.04e-05	2.94e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—IL2—atopic dermatitis	1.04e-05	2.94e-05	CbGpPWpGaD
Crizotinib—PTK2—Developmental Biology—IL6—atopic dermatitis	1.03e-05	2.92e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CD8A—atopic dermatitis	1.03e-05	2.91e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—NFKBIA—atopic dermatitis	1.03e-05	2.91e-05	CbGpPWpGaD
Crizotinib—MAPK7—Immune System—IL6—atopic dermatitis	1.03e-05	2.91e-05	CbGpPWpGaD
Crizotinib—LIMK1—Immune System—IL6—atopic dermatitis	1.03e-05	2.91e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—NGF—atopic dermatitis	1.02e-05	2.9e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—MAPK8—atopic dermatitis	1.02e-05	2.88e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CCL5—atopic dermatitis	1.02e-05	2.88e-05	CbGpPWpGaD
Crizotinib—YES1—Developmental Biology—IL6—atopic dermatitis	1.02e-05	2.88e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—IFNG—atopic dermatitis	1.02e-05	2.88e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—CD4—atopic dermatitis	1.02e-05	2.87e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—MAPK8—atopic dermatitis	1.02e-05	2.87e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CCR5—atopic dermatitis	1.01e-05	2.86e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—IFNG—atopic dermatitis	1e-05	2.84e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—NFKBIA—atopic dermatitis	9.99e-06	2.83e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CCR5—atopic dermatitis	9.97e-06	2.82e-05	CbGpPWpGaD
Crizotinib—JAK2—Axon guidance—IL6—atopic dermatitis	9.95e-06	2.82e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—CCR5—atopic dermatitis	9.93e-06	2.81e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NPS—atopic dermatitis	9.91e-06	2.8e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TAC1—atopic dermatitis	9.91e-06	2.8e-05	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—IL6—atopic dermatitis	9.9e-06	2.8e-05	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—IL6—atopic dermatitis	9.9e-06	2.8e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCR3—atopic dermatitis	9.84e-06	2.78e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—MAPK8—atopic dermatitis	9.82e-06	2.78e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—CD4—atopic dermatitis	9.82e-06	2.78e-05	CbGpPWpGaD
Crizotinib—LCK—Cytokine Signaling in Immune system—IL6—atopic dermatitis	9.8e-06	2.77e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—CD4—atopic dermatitis	9.76e-06	2.76e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—NFKBIA—atopic dermatitis	9.75e-06	2.76e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—NGF—atopic dermatitis	9.72e-06	2.75e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CXCR3—atopic dermatitis	9.72e-06	2.75e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—NFKBIA—atopic dermatitis	9.7e-06	2.74e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—CD4—atopic dermatitis	9.68e-06	2.74e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling by NGF—IL6—atopic dermatitis	9.63e-06	2.73e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CXCL10—atopic dermatitis	9.58e-06	2.71e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—IFNG—atopic dermatitis	9.51e-06	2.69e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CCR5—atopic dermatitis	9.45e-06	2.67e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—NGF—atopic dermatitis	9.43e-06	2.67e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—TNF—atopic dermatitis	9.4e-06	2.66e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—CXCL8—atopic dermatitis	9.39e-06	2.66e-05	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—IL6—atopic dermatitis	9.39e-06	2.66e-05	CbGpPWpGaD
Crizotinib—TYK2—Developmental Biology—IL6—atopic dermatitis	9.37e-06	2.65e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—TNF—atopic dermatitis	9.36e-06	2.65e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL18—atopic dermatitis	9.26e-06	2.62e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IFNG—atopic dermatitis	9.23e-06	2.61e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL5—atopic dermatitis	9.21e-06	2.61e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—IL2—atopic dermatitis	9.19e-06	2.6e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—CD4—atopic dermatitis	9.18e-06	2.6e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CCR5—atopic dermatitis	9.18e-06	2.6e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD8A—atopic dermatitis	9.12e-06	2.58e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—NFKBIA—atopic dermatitis	9.12e-06	2.58e-05	CbGpPWpGaD
Crizotinib—PTK2—Innate Immune System—IL6—atopic dermatitis	9.12e-06	2.58e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—IL1B—atopic dermatitis	9.07e-06	2.57e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—IL2—atopic dermatitis	9.03e-06	2.56e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—CD4—atopic dermatitis	8.99e-06	2.54e-05	CbGpPWpGaD
Crizotinib—YES1—Innate Immune System—IL6—atopic dermatitis	8.99e-06	2.54e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—IL2—atopic dermatitis	8.98e-06	2.54e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CXCL10—atopic dermatitis	8.97e-06	2.54e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—IL1B—atopic dermatitis	8.94e-06	2.53e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—CD4—atopic dermatitis	8.91e-06	2.52e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—IL2—atopic dermatitis	8.91e-06	2.52e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—TNF—atopic dermatitis	8.8e-06	2.49e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—CASP8—atopic dermatitis	8.79e-06	2.49e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TAC1—atopic dermatitis	8.77e-06	2.48e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NPS—atopic dermatitis	8.77e-06	2.48e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CASP8—atopic dermatitis	8.75e-06	2.48e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—CXCL8—atopic dermatitis	8.74e-06	2.47e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—CCR5—atopic dermatitis	8.7e-06	2.46e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—CD4—atopic dermatitis	8.64e-06	2.44e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—atopic dermatitis	8.64e-06	2.44e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—MAPK8—atopic dermatitis	8.6e-06	2.43e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CXCR3—atopic dermatitis	8.6e-06	2.43e-05	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—IL6—atopic dermatitis	8.59e-06	2.43e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—NFKBIA—atopic dermatitis	8.57e-06	2.42e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling by NGF—IL6—atopic dermatitis	8.53e-06	2.41e-05	CbGpPWpGaD
Crizotinib—IRAK1—Innate Immune System—IL6—atopic dermatitis	8.53e-06	2.41e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—IL1B—atopic dermatitis	8.48e-06	2.4e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—NFKBIA—atopic dermatitis	8.45e-06	2.39e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—IL2—atopic dermatitis	8.45e-06	2.39e-05	CbGpPWpGaD
Crizotinib—TBK1—Immune System—IL6—atopic dermatitis	8.39e-06	2.37e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—IL2—atopic dermatitis	8.35e-06	2.36e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—MAPK8—atopic dermatitis	8.31e-06	2.35e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—IL6—atopic dermatitis	8.31e-06	2.35e-05	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—IL6—atopic dermatitis	8.28e-06	2.34e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCL5—atopic dermatitis	8.25e-06	2.33e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IL1B—atopic dermatitis	8.23e-06	2.33e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—CD4—atopic dermatitis	8.23e-06	2.33e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CASP8—atopic dermatitis	8.23e-06	2.33e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IL2—atopic dermatitis	8.2e-06	2.32e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—MAPK8—atopic dermatitis	8.2e-06	2.32e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL5—atopic dermatitis	8.16e-06	2.31e-05	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—IL6—atopic dermatitis	8.05e-06	2.28e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—NFKBIA—atopic dermatitis	8.01e-06	2.27e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—NFKBIA—atopic dermatitis	7.99e-06	2.26e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CXCL10—atopic dermatitis	7.86e-06	2.22e-05	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—CXCL8—atopic dermatitis	7.84e-06	2.22e-05	CbGpPWpGaD
Crizotinib—ABCB1—Transmembrane transport of small molecules—PPARA—atopic dermatitis	7.81e-06	2.21e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—CXCL8—atopic dermatitis	7.79e-06	2.2e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—NFKBIA—atopic dermatitis	7.78e-06	2.2e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—MAPK8—atopic dermatitis	7.78e-06	2.2e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCL5—atopic dermatitis	7.72e-06	2.18e-05	CbGpPWpGaD
Crizotinib—SRC—Axon guidance—IL6—atopic dermatitis	7.72e-06	2.18e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—CCR5—atopic dermatitis	7.7e-06	2.18e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—MAPK8—atopic dermatitis	7.69e-06	2.17e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—CXCL8—atopic dermatitis	7.67e-06	2.17e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NGF—atopic dermatitis	7.64e-06	2.16e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—MAPK8—atopic dermatitis	7.62e-06	2.15e-05	CbGpPWpGaD
Crizotinib—JAK3—Immune System—IL6—atopic dermatitis	7.59e-06	2.15e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—IL6—atopic dermatitis	7.59e-06	2.15e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—IL6—atopic dermatitis	7.55e-06	2.14e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—MAPK8—atopic dermatitis	7.55e-06	2.14e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—IL6—atopic dermatitis	7.51e-06	2.12e-05	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—IL2—atopic dermatitis	7.49e-06	2.12e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—IFNG—atopic dermatitis	7.47e-06	2.11e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—IL2—atopic dermatitis	7.44e-06	2.11e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IFNG—atopic dermatitis	7.44e-06	2.1e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCR5—atopic dermatitis	7.43e-06	2.1e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—CXCL8—atopic dermatitis	7.34e-06	2.08e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—IL2—atopic dermatitis	7.33e-06	2.08e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—CD4—atopic dermatitis	7.22e-06	2.04e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CASP8—atopic dermatitis	7.21e-06	2.04e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CD4—atopic dermatitis	7.19e-06	2.03e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NGF—atopic dermatitis	7.15e-06	2.02e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—CXCL8—atopic dermatitis	7.12e-06	2.02e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—CXCL8—atopic dermatitis	7.12e-06	2.01e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—IL6—atopic dermatitis	7.1e-06	2.01e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—NFKBIA—atopic dermatitis	7.07e-06	2e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL2—atopic dermatitis	7.02e-06	1.99e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IFNG—atopic dermatitis	6.99e-06	1.98e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCR5—atopic dermatitis	6.96e-06	1.97e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CXCL10—atopic dermatitis	6.95e-06	1.97e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GLB1—atopic dermatitis	6.95e-06	1.96e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—MAPK8—atopic dermatitis	6.85e-06	1.94e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—TNF—atopic dermatitis	6.82e-06	1.93e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL2—atopic dermatitis	6.81e-06	1.93e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL2—atopic dermatitis	6.8e-06	1.92e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—IL6—atopic dermatitis	6.79e-06	1.92e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—IL6—atopic dermatitis	6.77e-06	1.91e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCL5—atopic dermatitis	6.76e-06	1.91e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CD4—atopic dermatitis	6.76e-06	1.91e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—MAPK8—atopic dermatitis	6.75e-06	1.91e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—IL6—atopic dermatitis	6.7e-06	1.9e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—IL6—atopic dermatitis	6.67e-06	1.89e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—IL6—atopic dermatitis	6.67e-06	1.89e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL1B—atopic dermatitis	6.67e-06	1.89e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ADSL—atopic dermatitis	6.66e-06	1.88e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—IL6—atopic dermatitis	6.64e-06	1.88e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL2—atopic dermatitis	6.64e-06	1.88e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL1B—atopic dermatitis	6.64e-06	1.88e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL2—atopic dermatitis	6.61e-06	1.87e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—IL6—atopic dermatitis	6.55e-06	1.85e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—IL6—atopic dermatitis	6.51e-06	1.84e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—IL6—atopic dermatitis	6.49e-06	1.84e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—MAPK8—atopic dermatitis	6.46e-06	1.83e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CASP8—atopic dermatitis	6.38e-06	1.8e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NFKBIA—atopic dermatitis	6.3e-06	1.78e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—IL6—atopic dermatitis	6.27e-06	1.77e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—MAPK8—atopic dermatitis	6.27e-06	1.77e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NGF—atopic dermatitis	6.26e-06	1.77e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL1B—atopic dermatitis	6.24e-06	1.77e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—CD4—atopic dermatitis	6.24e-06	1.76e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL2—atopic dermatitis	6.22e-06	1.76e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—IFNG—atopic dermatitis	6.13e-06	1.73e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—MAPK8—atopic dermatitis	6.11e-06	1.73e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CXCL8—atopic dermatitis	6.11e-06	1.73e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCR5—atopic dermatitis	6.09e-06	1.72e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—MAPK8—atopic dermatitis	6.09e-06	1.72e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CXCL8—atopic dermatitis	6.03e-06	1.7e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCL5—atopic dermatitis	5.99e-06	1.69e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CD4—atopic dermatitis	5.92e-06	1.67e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NFKBIA—atopic dermatitis	5.9e-06	1.67e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL2—atopic dermatitis	5.84e-06	1.65e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL2—atopic dermatitis	5.76e-06	1.63e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—MAPK8—atopic dermatitis	5.72e-06	1.62e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CXCL8—atopic dermatitis	5.72e-06	1.62e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CXCL8—atopic dermatitis	5.55e-06	1.57e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NGF—atopic dermatitis	5.54e-06	1.57e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—IL6—atopic dermatitis	5.51e-06	1.56e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—IL6—atopic dermatitis	5.49e-06	1.55e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL1B—atopic dermatitis	5.46e-06	1.55e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—CD4—atopic dermatitis	5.46e-06	1.55e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL2—atopic dermatitis	5.46e-06	1.55e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL2—atopic dermatitis	5.44e-06	1.54e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—IFNG—atopic dermatitis	5.42e-06	1.53e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCR5—atopic dermatitis	5.39e-06	1.53e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MAPK8—atopic dermatitis	5.38e-06	1.52e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—IL6—atopic dermatitis	5.31e-06	1.5e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL2—atopic dermatitis	5.3e-06	1.5e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MAPK8—atopic dermatitis	5.3e-06	1.5e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—IL6—atopic dermatitis	5.28e-06	1.49e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD4—atopic dermatitis	5.24e-06	1.48e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—IL6—atopic dermatitis	5.24e-06	1.48e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NFKBIA—atopic dermatitis	5.16e-06	1.46e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MAPK8—atopic dermatitis	5.03e-06	1.42e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—MAPK8—atopic dermatitis	5.01e-06	1.42e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—IL6—atopic dermatitis	4.97e-06	1.4e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—IL6—atopic dermatitis	4.91e-06	1.39e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MAPK8—atopic dermatitis	4.88e-06	1.38e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—IL6—atopic dermatitis	4.86e-06	1.38e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PPARA—atopic dermatitis	4.85e-06	1.37e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL1B—atopic dermatitis	4.84e-06	1.37e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—CD4—atopic dermatitis	4.84e-06	1.37e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IL6—atopic dermatitis	4.82e-06	1.36e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL2—atopic dermatitis	4.82e-06	1.36e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NFKBIA—atopic dermatitis	4.57e-06	1.29e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CXCL8—atopic dermatitis	4.49e-06	1.27e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—IL6—atopic dermatitis	4.45e-06	1.26e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—MAPK8—atopic dermatitis	4.44e-06	1.26e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—IL6—atopic dermatitis	4.37e-06	1.24e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—IL6—atopic dermatitis	4.31e-06	1.22e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL2—atopic dermatitis	4.29e-06	1.21e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CXCL8—atopic dermatitis	4.21e-06	1.19e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL6—atopic dermatitis	4.13e-06	1.17e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL2—atopic dermatitis	4.02e-06	1.14e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL6—atopic dermatitis	4e-06	1.13e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL6—atopic dermatitis	4e-06	1.13e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MAPK8—atopic dermatitis	3.95e-06	1.12e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL6—atopic dermatitis	3.9e-06	1.1e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL6—atopic dermatitis	3.89e-06	1.1e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MAPK8—atopic dermatitis	3.7e-06	1.05e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CXCL8—atopic dermatitis	3.68e-06	1.04e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PPARA—atopic dermatitis	3.66e-06	1.04e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL6—atopic dermatitis	3.65e-06	1.03e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL2—atopic dermatitis	3.52e-06	9.96e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL6—atopic dermatitis	3.43e-06	9.71e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL6—atopic dermatitis	3.39e-06	9.58e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—IL6—atopic dermatitis	3.37e-06	9.54e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CXCL8—atopic dermatitis	3.26e-06	9.22e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MAPK8—atopic dermatitis	3.24e-06	9.17e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL6—atopic dermatitis	3.21e-06	9.08e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL6—atopic dermatitis	3.2e-06	9.05e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL6—atopic dermatitis	3.12e-06	8.82e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL2—atopic dermatitis	3.12e-06	8.82e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—IL6—atopic dermatitis	2.95e-06	8.36e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MAPK8—atopic dermatitis	2.87e-06	8.11e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL6—atopic dermatitis	2.83e-06	8.01e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—IL6—atopic dermatitis	2.62e-06	7.4e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL6—atopic dermatitis	2.52e-06	7.14e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL6—atopic dermatitis	2.36e-06	6.68e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PPARA—atopic dermatitis	2.25e-06	6.38e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL6—atopic dermatitis	2.07e-06	5.85e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL6—atopic dermatitis	1.83e-06	5.18e-06	CbGpPWpGaD
